Summary:
- The article discusses a significant medical breakthrough involving the use of a novel drug, "Lecanemab," which has shown the ability to slow cognitive decline in patients diagnosed with early-stage Alzheimer's disease.
- It highlights the clinical trial results demonstrating that the treatment targets amyloid plaques in the brain, providing a potential shift in the therapeutic landscape for neurodegenerative diseases.